<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>In pediatric mature B-cell non-Hodgkin <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, international pathologist diagnostic agreement was previously evaluated using the Revised European-American <z:hpo ids='HP_0002665'>Lymphoma</z:hpo> Classification </plain></SENT>
<SENT sid="1" pm="."><plain>Surgical biopsy histology technical quality (HTQ) is variable and may affect diagnostic accuracy </plain></SENT>
<SENT sid="2" pm="."><plain>This study evaluated diagnostic agreement correlated with HTQ </plain></SENT>
<SENT sid="3" pm="."><plain>Surgical biopsies obtained from international protocol FAB LMB96 Treatment of Mature B-Cell <z:hpo ids='HP_0002665'>Lymphoma</z:hpo>/<z:hpo ids='HP_0001909'>Leukemia</z:hpo> for Burkitt <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e>), diffuse large B-cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DLBCL</z:e>), and high-grade B-cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo> Burkitt-like (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BLL</z:e>), were independently reviewed by hematopathologists from 3 national groups (Children's <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">Cancer</z:e> Group, Société Française d'Oncologie Pédiatrique, and United Kingdom Children's <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">Cancer</z:e> Study Group) to determine each national diagnosis and a final diagnosis </plain></SENT>
<SENT sid="4" pm="."><plain>HTQ grades for microscopic tissue sections included: good; medium; low; inconclusive </plain></SENT>
<SENT sid="5" pm="."><plain>Final diagnoses in 187 cases included: <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> 87 (47%); <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BLL</z:e> 20 (11%); <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DLBCL</z:e> 64 (34%); other 16 (9%) </plain></SENT>
<SENT sid="6" pm="."><plain>HTQ grades included: good 10 (5%); medium 100 (54%); low 75 (40%); inconclusive 2 (1%) </plain></SENT>
<SENT sid="7" pm="."><plain>The rate of uniform agreement between the national diagnoses was significantly higher with good or medium HTQ (62%) than with low HTQ (33%) (P = 0.001) </plain></SENT>
<SENT sid="8" pm="."><plain>In conclusion, in pediatric mature B-cell non-Hodgkin <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, international pathologist diagnostic agreement is significantly higher in surgical biopsies with better HTQ </plain></SENT>
<SENT sid="9" pm="."><plain>Poor HTQ may adversely impact diagnostic ability and affect prognosis and therapeutic management when different treatment regimens are employed for <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DLBCL</z:e> versus <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e>/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BLL</z:e> </plain></SENT>
</text></document>